Celastrol inhibits intestinal lipid absorption by reprofiling the gut microbiota to attenuate high-fat diet-induced obesity
INTRODUCTION

In recent decades, changes in the amount and composition of dietary fat have led to the current prevalence of obesity worldwide (Collaborators et al., 2017; Cordain et al., 2005). Obesity is a major risk factor for type 2 diabetes, cardiovascular disease, high blood pressure, nonalcoholic steatohepatitis, and even cancers (Ishlam and James, 2005; Olshansky et al., 2005). Although some weight-loss drugs have been developed, they often do not work well or have serious side effects (Padwal and Majumdar, 2007). Therefore, it is urgent to develop new drugs for the treatment of obesity and its complications.

Celastrol, a compound extracted from traditional Chinese medicine, has been reported as a potent anti-obesity agent with controversial mechanisms. Here both C57BL/6J and leptin-deficient (ob/ob) mice fed a high-fat diet (HFD) displayed body weight loss after celastrol therapy, opposing the previous viewpoint that celastrol improves obesity by sensitizing leptin signaling. More importantly, celastrol downregulated lipid transporters in the intestine, increased lipid excretion in feces, and reduced body weight gain in HFD mice. Meanwhile, analysis of gut microbiota revealed that celastrol altered the gut microbiota composition in HFD-fed mice, and modulating gut microbiota by antibiotics or fecal microbiota transplantation blocked the celastrol effect on intestinal lipid transport and body weight gain, suggesting a critical role of the gut microbiota composition in mediating the anti-obesity role of celastrol under HFD. Together, the findings revealed that celastrol reduces intestinal lipid absorption to antagonize obesity by resetting the gut microbiota profile under HFD feeding.

SUMMARY

Celastrol inhibits intestinal lipid absorption by reprofiling the gut microbiota to attenuate high-fat diet-induced obesity

Hu Hua, Yue Zhang, Fei Zhao, Ke Chen, Tong Wu, Qianqi Liu, Songming Huang, Aihua Zhang, and Zhanjun Jia

1Nanjing Key Laboratory of Pediatrics, Children’s Hospital of Nanjing Medical University, Guangzhou Road #72, Nanjing 210008, P. R. of China
2Department of Nephrology, Children’s Hospital of Nanjing Medical University, Guangzhou Road #72, Nanjing 210008, P. R. of China
3Jiangsu Key Laboratory of Pediatrics, Nanjing Medical University, Nanjing 210029, P. R. of China
4Department of Endocrinology, Children’s Hospital of Nanjing Medical University, Guangzhou Road #72, Nanjing 210008, China
5These authors contributed equally
6These authors contributed
7Lead contact

*Correspondence: smhuang@njmu.edu.cn (S.H.), zhaihua@njmu.edu.cn (A.Z.), jiazj72@hotmail.com (Z.J.)
https://doi.org/10.1016/j.isci.2021.102077
the report of Liu and colleagues (Liu et al., 2015). To our surprise, we did not detect a significant upregulation of the intestinal microbial profile and intestinal lipid absorption, which reveals a mechanism of the intestinal lipid excretion of high-fat diet (HFD)-fed mice was increased by celastrol, accompanying changes in intestinal microbial composition and decreased expression of transporters related to intestinal lipid absorption, suggesting that celastrol may achieve its weight loss effect through regulation of the intestinal microbial profile and intestinal lipid absorption, which reveals a mechanism of celastrol in the treatment of obesity.

It is well known that there are many factors affecting diet-induced obesity, including food intake (Liu et al., 2015), nutrient absorption through the gastrointestinal tract (Li et al., 2016), the composition of intestinal microbiorganisms (Martinez-Guryn et al., 2018), lipid deposition and lipolysis (Wei et al., 2019), and energy expenditure (Sidsosis et al., 2015). In our present study, both in vivo and in vitro data did not support that celastrol exerts its weight loss function by regulating energy expenditure. However, we found a striking phenotype that the intestinal lipid excretion of high-fat diet (HFD)-fed mice was increased by celastrol, accompanied by changes in intestinal microbial composition and decreased expression of transporters related to intestinal lipid absorption, suggesting that celastrol may achieve its weight loss effect through regulation of the intestinal microbial profile and intestinal lipid absorption, which reveals a mechanism of celastrol in the treatment of obesity.

RESULTS
Celastrol protects C57BL/6 mice from HFD-induced obesity
We first confirmed the effect of celastrol as a weight loss agent. In our study, HFD-fed C57BL/6 mice with an average BW of 46 g were orally administered 3 mg/kg/day celastrol by mixing the drug into high-fat chow for 21 days. Consistent with the reported phenotype, the mice in the experimental group lost approximately 22% of BW compared with the control group (Figures 1A and 1B). The size and weight of the epididymal fat depots (eWAT), inguinal fat depots (iWAT), perirenal fat depots (pWAT) and BAT, as well as the size of adipocytes of eWAT and BAT in the celastrol intervention group were less than those in the control group (Figures 1C–1H). We also observed that celastrol intervention reduced liver volume in DIO mice, significantly improved liver steatosis evidenced by H&E and Oil red O (ORO) staining (Figure S3A), and reduced liver weight and triglycerides (TG) levels (Figures S3B and S3C). The GTT results showed that the glucose metabolism of the mice treated with celastrol was significantly improved (Figures 1I and 1J). In this model, we also observed that the food intake of the mice treated with celastrol was reduced, but the level of leptin in blood was not changed significantly (Figures 1K and 1L), which was consistent with the report of Liu and colleagues (Liu et al., 2015). To our surprise, we did not detect a significant upregulation of mitochondrial and energy-expenditure-related genes in brown fat, which have been reported to be upregulated by celastrol (Ma et al., 2015) (Figure 1M). All these data confirmed a potent anti-obesity effect of celastrol.

Celastrol-induced weight loss is independent of the upregulation of UCP1 and energy expenditure
Celastrol protects against obesity and metabolic dysfunction by increasing energy expenditure (Ma et al., 2015). The results from our experiments showed that celastrol-induced weight loss was not accompanied by significant upregulation of the mitochondrial and brown fat genes, prompting us to further verify the impact of celastrol on energy expenditure using a combined indirect calorimetry system. Two groups of male mice aged 8 weeks were fed a HFD or HFD supplemented with celastrol (3 mg/kg/day) for two weeks, and then the energy expenditure and home-cage activity of these mice were examined using the TSE system. The results showed that administration of celastrol had little effect on O2 consumption, CO2
Figure 2. Celastrol reduces intestinal lipid absorption in DIO C57BL/6 mice

(A–G) HFD-fed obese C57BL/6 mice were subjected to oral administration of celastrol (3 mg/kg/day) for 3 weeks. (A and B) Representative pictures for (A) the peritoneal cavity and (B) isolated intestines of mice treated with celastrol or not. (C) Representative H&E-stain images of the intestine (400×). Scale bar, 20 μm. (D and E) Relative fecal TG and 24 h TG excretion levels of mice treated with celastrol or not (n = 8 for each group). (F and G) Relative fecal FFA and 24 h FFA excretion levels of mice treated with celastrol or not (n = 8 for each group). (H) BW of mice on HFD, either without (HFD, n = 7) or treated with celastrol at doses of 3 mg/kg/day (HFD + CEL, n = 7). (I) Plasma TG levels of mice on HFD, either without (HFD, n = 7) or treated with celastrol at doses of 3 mg/kg/day (HFD + CEL, n = 7) before and 2 h after administration of olive oil by gavage. (J) Macroscopic view of representative plasma of mice on HFD, either without (HFD) or treated with celastrol at doses of 3 mg/kg/day (HFD + CEL) 2 h after administration of olive oil by gavage. (K) BW of mice on ND, either without (ND, n = 6) or treated with celastrol at doses of 3 mg/kg/day (ND + CEL, n = 6).
production, the respiratory exchange rate, and heat production (Figures S1A–S1G), as well as the cumulative moving distance (Figure S1H). Next, we evaluated the effect of celastrol on brown fat at the cellular level. Primary brown fat precursor cells were isolated, and the safe doses of celastrol ranging from 0 to 600 nM were determined based on the cell viability results (Figure S2A). First, we studied the effects of celastrol on differentiated mature brown adipocytes induced in vitro. The qRT-PCR results showed that 50 nM or 100 nM celastrol treatment for 48 h or 96 h did not further upregulate the expression of the mitochondrial and brown fat genes but downregulated the expression of the most important thermogenic gene UCP1 (Figures S2B and S2C). The protein levels of UCP1 were confirmed by WB (Figure S2D). Given that obesity is often accompanied by whitening of brown fat, leading to a decline of brown fat function (Shimizu et al., 2014), we then mimicked the process of whitening of brown fat in vitro by stimulating differentiated mature brown fat cells with free fatty acids (FFAs). The WB results showed that FFA (200 μM) significantly downregulated the protein expression level of UCP1 in mature brown adipocytes, but treatment with 50 nM and 100 nM celastrol for 24, 48, 72, or 96 h aggravated the FFA-induced downregulation of UCP1 at the protein level (Figure S2E). Overall, these results suggest that the weight loss effect of celastrol was possibly not due to the increment of UCP1 and energy expenditure.

Celastrol reduces intestinal lipid absorption in DIO C57BL/6 mice

Although we have not confirmed that celastrol works by enhancing energy expenditure, we noticed that the intestines of the DIO mice treated with celastrol orally were filled with a large amount of green content similar to the color of the high-fat food we used, but this phenomenon was not observed in mice from the control group (Figure 2A). From the isolated intestines of mice, we observed more clearly that there was more food residue in the intestine of the celastrol-treated DIO mice. These food residues did not form granular feces but instead appeared mushy (Figure 2B). This prompted us to analyze the fecal components, especially the TG and FFA levels, and we found that the TG and FFA levels in the feces of mice from the celastrol-treated group were significantly higher than those in the control group (Figures 2D and 2F), which is consistent with our observations. Similarly, based on the 24-h defecation volume, celastrol-treated mice also showed higher TG and FFA excretion (Figures 2E and 2G). The pathological observation of intestinal tissues revealed that the intestines of the mice in the celastrol-treated group were denser and contained fewer vesicular structures than the intestines of the control group (Figure 2C). These phenomena suggested that celastrol may have an effect on mouse intestinal absorption of lipids from high-fat food. Next, we evaluated the effect of celastrol on intestinal lipid absorption through an acute experiment that examined the changes in plasma TG levels in mice administered oral olive oil (Li et al., 2016). After pretreatment of the DIO mice with celastrol for 6 days, the BW of the mice was significantly decreased compared with that of the control group (Figure 2H). In these mice, 2 h after olive oil gavage, the plasma of mice in the drug-administration group looked more transparent, and the plasma TG levels of the DIO mice treated with celastrol were significantly lower than those in the control group (Figures 2I and 2J). However, in ND-fed mice, 6 days of administration of celastrol did not alter the BW (Figure 2K), and the plasma TG levels of the two groups were not significantly different 2 h after olive oil gavage (Figure 2L).

In a separate experiment, we treated the HFD-fed mice with celastrol by intraperitoneal injection instead of oral administration, which ensures the absorption of the drug into the circulation and avoids the direct contact between celastrol and lipids in food. The results showed that intraperitoneal administration of celastrol also decreased body weight of HFD-fed mice without significant reduction in food intake (Figures S4A and S4B), accompanied by a significant reduction of the weight of eWAT and liver in HFD + CEL group compared with HFD group (Figures S4C and S4D). Meanwhile, the mice with i.p. injection of celastrol exhibited the same intestinal phenotype as the mice treated with celastrol orally (Figure S4E). The levels of TG and FFA in feces of mice injected with celastrol were significantly increased (Figures S4F and S4G), which was accompanied by the significantly downregulated expression of intestinal lipid transporter genes of CD36, FATP4, and FATP2 (Figures S4H–S4J). These results demonstrated that celastrol does affect the absorption of lipids in the intestine under high-fat food challenge.
Figure 3. Celastrol inhibits the expression of intestinal lipid transport-related genes in DIO C57BL/6 mice

(A–C) The intestinal protein of mice was identified and analyzed by proteomics. (A) The volcano plot is used to show significant differences between the two sets of sample data (n = 3 for each group). Red dots represent significantly differentially expressed proteins (fold changes greater than 1.2-fold and p value < 0.05), with black dots representing proteins with no differential changes. (B) Heatmaps representing the selected 21 significantly differentially expressed proteins. Red represents significantly upregulated proteins, and blue represents significantly downregulated proteins. (C) KEGG enrichment was used to analyze the effect of celastrol on protein expression in the intestine of DIO C57BL/6 mice treated with celastrol or not (n = 3 for each group). The number on the right of the column on the histogram represents the enrichment factor. The enriched KEGG pathways with p < 0.05 are shown.

(D–K) mRNA levels of intestinal lipid and glucose-transport-related genes of mice treated with celastrol or not (n = 8 for each group). The genes included CD36 (D), FATP4 (E), ApoB (F), FATP2 (G), PPARα (H), GLUT2 (I), GLUT5 (J), and SGLT1 (K).

(L and M) Lipid- and glucose-transport-related protein levels and (M) quantified signal intensity. Error bars represent the mean ± SEM. p values were determined by Student’s t test. *p < 0.05, **p < 0.01, ***p < 0.001; n.s., not significant (p > 0.05).

Celastrol inhibits the expression of intestinal lipid transporters in DIO C57BL/6 mice

The intestinal absorption of lipids requires the participation of a series of proteins, such as lipid transporters (Abumrad and Davidson, 2012). Because celastrol inhibits the intestinal absorption of lipids, it is reasonable to perform a comprehensive study to explore whether celastrol has an effect on lipid-absorption-related proteins of the intestine by TMT-based LC-MS/MS analysis. The results showed that a total of 4,248 proteins were identified by one or more unique peptides. The protein ratio was obtained by comparing the control (HFD) group with the celastrol-treated (CEL) group. Among the differentially expressed proteins, 115 proteins were upregulated and 297 proteins were downregulated in the CEL group compared with the HFD group (Data S1 and Figure 3A). We found that a large number of proteins related to lipid absorption, including apolipoprotein B-100 (ApoB), very-long-chain acyl-CoA synthetase (FATP2), long-chain fatty acid transport protein 4 (FATP4), and fatty acid-binding protein (Fabp2), were downregulated by administration of celastrol. Some of the differential concentrations of proteins between the two groups were visualized using a global heatmap analysis (Figure 3B), and the protein ID, protein name, gene name, and relative abundance ratios of these differentially expressed proteins are listed in Table 1. We next performed KEGG analysis to investigate the enriched pathways in which the upregulated and downregulated proteins participated in response to celastrol treatment. Among the enriched pathways evaluated by p value, the fat digestion and absorption pathways were significantly affected (Figure 3C).

Next, we verified the nutrient-absorption-related genes in the small intestine by qRT-PCR and/or WB as follows: ApoB, FATP2 (encoded by the Slc27a2 gene), and FATP4 (encoded by the Slc27a4 gene) for lipid absorption (Losacco et al., 2018) and SGLT1, GLUT2, and GLUT5 for carbohydrate absorption. The results showed that celastrol treatment significantly downregulated ApoB expression at both the mRNA and protein levels (Figures 3E, 3G, 3L, and 3M). The expression of FATP2 and FATP4 was downregulated at the protein level rather than at the mRNA level (Figures 3E, 3G, 3L, and 3M). This is consistent with the proteomics analysis. In addition, we examined CD36, an important lipid transporter, which was also significantly downregulated at both the mRNA and protein levels (Figures 3D, 3L, and 3M). However, the transporters for carbohydrates, namely, SGLT1, GLUT2, and GLUT5, were not significantly altered by celastrol treatment at either the mRNA or the protein level (Figures 3I–3K, 3L, and 3M). The transcription factor peroxisome proliferator-activated receptor (PPAR) can regulate the expression of some nutrient transporters (Lynes and Widmaier, 2011). PPARα, the major isoform expressed in the intestine (de Vogel-van den Bosch et al., 2008), was decreased significantly in the celastrol-treated group (Figures 3H, 3L, and 3M). In order to explore whether celastrol affected digestive functions as well as absorptive functions, we detected enterocyte-related genes of cholecystokinin (Cck), secretin (Sct), and gastric inhibitory polypeptide (Gip) by qRT-PCR, and the results showed that celastrol significantly downregulated Sct and Gip mRNA levels without affecting Cck (Figures S5A–S5C). We next checked the data of proteomics of intestine from HFD and HFD + CEL mice and found that the level of GIP protein was significantly downregulated with a trend reduction of SCT protein in the HFD + CEL group (Figures S5D and S5E). However, CCK protein was not detected in this proteomics assay. These results suggest that the inhibition of intestinal lipid absorption by celastrol is related to the downregulation of lipid digestion- and transport-related genes.

Celastrol reduces the BW of ob/ob mice fed an HFD

Previous reports have shown that celastrol is a sensitizer for leptin and has no weight loss effect on ob/ob or db/db mice (Feng et al., 2019; Liu et al., 2015). In general, the obesity of ob/ob or db/db mice was
caused by an increase in food intake of ND but not HFD chow due to the lack of leptin or leptin receptor. If celastrol reduces BW by inhibiting intestinal lipid absorption, as suggested by our data above, it should also reduce the BW of \textit{ob/ob} mice when they are fed HFD chow. To explore this issue, we fed 4-week-old \textit{ob/ob} mice with an average BW of 19.95 ± 0.2846 g with HFD chow, and 3 weeks later, the average BW of the mice reached 46.06 ± 0.4831 g. These mice were randomly divided into two groups: one group of mice was fed HFD chow containing the same concentration of celastrol (55.2 ppm) as used in DIO C57BL/6 mice, and another group of mice continuing on the HFD were used as the controls. At the end of the sixth week, the body size of the mice in the administration group appeared to be smaller than that of the control group (Figure 4A), and the BW of mice in the control group reached 61.05 ± 1.489 g, but the mice in the drug-administered group weighed only 53.47 ± 1.081 g, which was approximately 12.4% less than that in the control group (Figure 4B). Figure 4D shows the gross appearance of eWAT, iWAT, pWAT, and BAT. Both iWAT and pWAT were significantly reduced in size, which is consistent with the weight of these tissues (Figures 4E–4H). The effect of celastrol on these mice was not accompanied by significant changes in food intake (Figure 4C). In addition, the gross appearance of the liver showed that HFD exposure caused an increase in liver volume accompanied by a lightening of the color in ob/ob mice. Histologically,

### Table 1. Key differentially expressed proteins identified by tandem mass tag-based proteomics analysis between DIO mice fed with or without celastrol

| Protein ID  | Protein name (Gene name)                                                                 | FC value | p-value |
|-------------|----------------------------------------------------------------------------------------|----------|---------|
| Q99JY8      | Phospholipid phosphatase 3 (Plpp3)                                                     | 0.81294  | 0.0069  |
| E9Q414      | Apolipoprotein B-100 (Apolob)                                                          | 0.802762 | 0.0344  |
| Q61469      | Phospholipid phosphatase 1 (Plpp1)                                                     | 0.776152 | 0.0087  |
| Q91VE0      | Long-chain fatty acid transport protein 4 (Sic27a4)                                     | 0.663703 | 0.0116  |
| Q8OW94      | 2-Acylglycerol O-acyltransferase 2 (Mogat2)                                            | 0.602726 | 0.0417  |
| P06728      | Apolipoprotein A-IV (Apoa4)                                                            | 0.544414 | 0.0208  |
| O08601      | Microsomal triglyceride transfer protein large subunit (Mtp)                           | 0.513655 | 0.0155  |
| P5S050      | Fatty acid-binding protein, intestinal (Fabp2)                                         | 0.400546 | 0.0031  |
| P12710      | Fatty acid-binding protein, liver (Fabp1)                                              | 0.334806 | 0.0063  |
| P41216      | Long-chain fatty acid CoA ligase 1 (Acs1)                                              | 0.82888  | 0.0351  |
| P45952      | Medium-chain specific acyl-CoA dehydrogenase, mitochondrial (Acadm)                    | 0.814053 | 0.0038  |
| P52825      | Carnitine O-palmitoyltransferase 2, mitochondrial (Cpt2)                                | 0.788776 | 0.0138  |
| O35488      | Very-long-chain acyl-CoA synthetase (Sic27a2)                                          | 0.715861 | 0.0489  |
| Q921H8      | 3-Ketoacyl-CoA thiolase A, peroxisomal (Acaa1a)                                         | 0.702893 | 0.0254  |
| P06801      | NADP-dependent malic enzyme (MeT)                                                      | 0.698114 | 0.0125  |
| Q9DBM2      | Peroxisomal bifunctional enzyme (Ehhadh)                                              | 0.675939 | 0.0135  |
| Q9R0HO      | Peroxisomal acyl-coenzyme A oxidase 1 (Acot1)                                          | 0.652622 | 0.0139  |
| Q64516      | Glycerol kinase (Gk)                                                                   | 0.649668 | 0.0087  |
| P32020      | Nonspecific lipid-transfer protein (Scp2)                                              | 0.544846 | 0.0245  |
| Q922V4      | Phosphoenolpyruvate carboxykinase, cytosolic [GTP] (Pck1)                             | 0.483453 | 0.0010  |
| Q8LJ80      | Long-chain fatty acid CoA ligase 5 (Acs1)                                              | 0.42567  | 0.0156  |

FC, fold change; HFD, high-fat diet; CEL, celastrol. Related to Figure 3.

*The FC value was calculated as the ratio of the average mass response (area) between the two groups (FC value = CEL/HFD). Thus, FC values > 1 indicate significantly higher levels in the CEL group than in the HFD group, whereas FC values < 1 indicate significantly lower levels in the CEL group.

*Only proteins with FC values greater than ±1.2 and p values less than 0.05 were deemed statistically significant.
the H&E staining and ORO staining results showed ballooning degeneration of liver cells, and massive accumulation of large lipid droplets was found in the livers of these mice. All these phenotypes were clearly reversed by celastrol treatment (Figure S3D). The significant decrease in liver weight and TG level of celastrol-treated ob/ob mice matched the change in liver gross appearance and pathological examination (Figure S3E and S3F). The GTT results showed that celastrol-treated ob/ob mice demonstrated faster glucose clearance than the control mice (Figure 4I), and the total systemic glucose (represented by the area under the curve (AUC)) significantly decreased by 25.5% (Figure 4J). To assess whether the effects on mice were from drug toxicity under this condition, we tested the main biochemical indicators in the plasma of ob/ob mice. The results showed that celastrol did not significantly change the levels of BUN, SCR, and TG. At the same time, the levels of ALT, AST, LDH, and TC in plasma were significantly decreased (Figures S6A–S6G), which suggested that the BW-lowering effect of celastrol on ob/ob mice.
was not from drug toxicity, and the liver function of the mice was even improved based on reduced ALT and AST levels. All these phenotypes were consistent with the effects of celastrol on DIO C57BL/6 mice, further verifying that the weight loss effect of celastrol is food-type dependent but not leptin signaling dependent.

Celastrol downregulates the expression of lipid-absorption-related genes in the intestine of ob/ob mice fed an HFD

Consistent with the DIO C57BL/6 mice treated with celastrol, we also observed that there was more food residue in the intestine of the HFD-fed ob/ob mice administered celastrol, and these mice could not form granular faces in the colon (Figure 5A). The pathological morphology of the jejunum also became denser compared with the control mice (Figure 5B). Meanwhile, the fecal TG levels of ob/ob mice were significantly increased by celastrol administration (Figure 5C). Next, we tested the transcriptional levels
Figure 6. Early intervention with celastrol inhibits intestinal lipid absorption and prevents HFD-induced weight gain in C57BL/6 mice

(A–K) ND- or HFD-fed C57BL/6 mice were subjected to oral administration of celastrol (3 mg/kg/day) for 24 days. (A) The BW of each group of mice during the treatment (n = 10 for each group). (B) Macroscopic view of representative sections of eWAT, iWAT, pWAT, and BAT of each group of mice. (C–F) Weights of (C) eWAT, (D) iWAT, (E) pWAT, and (F) BAT of each group of mice (n = 10 for each group). (G) The average 3-day food intake of each group of mice during celastrol treatment (n = 10 for each group). (H) Relative fecal TG levels of each group of mice during celastrol treatment (n = 10 for each group). (I–J) Representative pictures of isolated intestines of celastrol-treated mice (I) on an ND or (J) HFD. (K) Representative H&E-stained images of the intestine (200 X). Scale bar, 50 μm. Error bars represented the mean ± SEM. p values were determined by two-way ANOVA. ***p < 0.001, **p < 0.01, *p < 0.05; n.s., not significant (p > 0.05).
of lipid transporters, including CD36, FATP2, and FATP4, in the small intestine of ob/ob mice and found that all these genes were also significantly downregulated (Figures 5D–5F), and the protein levels of CD36, FATP2, and FATP4 were confirmed by WB (Figures 5G and 5H). Combined with the reported fact that celastrol had no effect on the BW of ob/ob mice on an ND, our data further demonstrate that celastrol inhibits lipid absorption of the intestinal tract by inhibiting the expression of lipid-transport-related genes.

Early intervention with celastrol prevents HFD-induced weight gain in C57BL/6 mice

Studies have shown that changes in many indicators, including glucose tolerance and the leptin pathway, occur secondarily to weight loss (Adams et al., 2017; Guven et al., 1999). Therefore, we performed a short-
Figure 8. Dietary celastrol beneficially alters the gut microbiota

(A–I) DIO mice (n = 7 for each group) or HFD-fed lean C57BL/6 mice (n = 10 for each group) were subjected to oral administration of celastrol (3 mg/kg/day). Mouse fecal samples were taken and subjected to 16S rRNA gene sequencing. (A and G) PCoA of Bray-Curtis dissimilarity for all samples from (A) DIO mice or (G) HFD-fed lean C57BL/6 mice. (B) Abundance of 52 microbial genera. (C) Relative abundance of 52 microbial genera. (D–F) Relative abundance of specific bacterial genera. (J–L) Relative abundance of specific bacterial genera. (M–P) PCoA of Bray-Curtis dissimilarity for all samples from (M) DIO mice or (P) HFD-fed lean C57BL/6 mice.
treated with celastrol or (G) early celastrol-treated HFD-fed lean mice. (B and H) Stacked bar graph showing the relative abundance of bacterial taxa (genus level) of samples from (B) DIO mice treated with celastrol or (H) early celastrol-treated HFD-fed lean mice. (C and I) Significantly different intestinal microbiota at the genus level (C) among lean, DIO, and celastrol-treated DIO mice (n = 7 for each group) or (I) among lean, HFD and early celastrol-treated mice on an HFD (treated at the beginning of HFD) (n = 10 for each group). (D–F and J–L) The top 20 microbial species with significant changes in (D–F) DIO mice treated with celastrol or (J–L) early celastrol-treated HFD-fed lean mice. (M–N) Principal coordinate analysis (PCoA) of all KOs that were significantly altered by celastrol treatment in (M) DIO mice or (N) early celastrol-treated HFD-fed lean mice. (O–P) Pathway enrichment analysis of all significantly altered KOs in (O) DIO mice treated with celastrol or (P) early celastrol-treated HFD-fed lean mice. Error bars represent the mean ± SEM. p values were determined by ANOVA. 0.01<*p < 0.05, 0.001<**p < 0.01, 0.0001< ***p < 0.001, ****p < 0.0001. ND, normal diet; HFD, high-fat diet; HFDC, high-fat diet supplemented with celastrol.

Early intervention with celastrol inhibits intestinal lipid absorption in C57BL/6 mice fed an HFD

Consistent with the effect of celastrol on the intestines of DIO mice, we still observed that early celastrol intervention significantly increased the fecal TG levels of mice on an HFD (Figure 6H), with no significant changes in food intake (Figure 6G). The intestinal appearance and pathological changes in celastrol-treated HFD rather than ND-fed mice were consistent with the DIO mice treated with celastrol (Figures 6I–6K). In view of the abnormalities in the mouse intestines, we further investigated whether the metabolism of the intestinal tissue was changed by LC-MS-based metabolomics analysis. The orthogonal partial least squares-discriminant analysis (OPLS-DA) result showed a clear separation between the HFD and HFDC groups (R2X = 0.366, R2Y = 0.993, and Q2 = 0.9) (Figure 7A). Moreover, a permutation test with 200 iterations confirmed that the constructed OPLS-DA model was valid and not overfitted, as the original right R2 and Q2 values were significantly higher than the corresponding permuted left values [R2 = (0.0, 0.9421), Q2 = (0.0, -0.1671)] (Figure 7B). As shown in Figure 7C, the volcanic maps obtained from the univariate analyses of fold change analysis and t test intuitively showed the significance of the changes in metabolites between the two groups of samples (the red dots in the figure are the metabolites with FC > 1.5 and p value <0.05, that is, the differential metabolites screened by univariate statistical analysis). Hierarchical clustering analysis showed that the significantly different metabolites shown in Figure 7D can represent the differences between different samples. The results of KEGG pathway enrichment analysis of differentially expressed metabolites in the HFD and HFDC groups showed that ABC transporters, arginine biosynthesis, central carbon metabolism in cancer, and other important pathways underwent significant changes (Figure 7E). These results suggest that celastrol may have value in altering intestinal metabolism and provide additional evidence that the drug has an impact on the intestines. The results of these early celastrol interventions indicated that the effect of celastrol on the intestines was not secondary to the enhanced leptin sensitivity and weight loss of mice.

Dietary celastrol beneficially alters the gut microbiota

Studies have shown that the intestinal flora itself not only affects the digestion of lipids but also regulates transporters related to intestinal lipid absorption (Chang and Martinez-Guryn, 2019; Kuang et al., 2019; Martinez-Guryn et al., 2018; Semova et al., 2012). To define the effects of dietary celastrol on the gut microbiome, we analyzed the composition, abundance, and function of the gut microbiota. The rarefaction curve analysis results showed that the OTU rarefaction curves reached a steady level, indicating that the libraries were large enough to obtain the major information of the bacterial diversity of all samples (Figures S8A and S8B). In the feces of DIO mice treated with celastrol for 5 weeks, principal coordinate analyses (PCoA) revealed a distinct clustering of microbiota composition between the ND, HFD, and celastrol-supplemented...
HFD (HFD-C) groups along the first principal component (PC1) (Figure 8A). To determine whether these microbial changes are secondary to improvements in obesity or direct effects of the drug, we treated HFD-fed lean mice with celastrol at an early stage for 24 days and still observed a distinct clustering of microbiota composition between the ND, HFD, and celastrol-supplemented HFD (HFD-C) groups along PC1 (Figure 8G). Histograms of the community structure at the genus level illustrate the significant changes in the relative composition of the fecal microbiota, whether in DIO mice treated with celastrol (Figure 8B and Data S2) or HFD-fed lean mice treated early with celastrol (Figure 8H and Data S3). At the genus level, a direct comparison of relative abundance showed that among the top 20 changed genera, celastrol intervention restored the changes in 13 genera caused by HFD in DIO mice (Figure 8C) and 13 genera caused by HFD in early celastrol-treated HFD-fed lean mice (Figure 8I). Notably, the abundance of the Akkermansia genus, which was reported to be negatively correlated with waist circumference, body weight, body mass index, overall fat content, ovarian fat, and leptin concentrations in the circulation (Axling et al., 2012; Kim et al., 2014), was significantly upregulated by celastrol to more than eight times compared with the ND group in DIO mice (Figure 8C). Fourteen identical genera were altered by celastrol intervention in both DIO mice (Figure 8C) and early celastrol-treated HFD-fed lean mice (Figure 8I). At the species level, of the top 20 species with significant changes in DIO mice (Figures 8D–8F) and early celastrol-treated HFD-fed lean mice (Figures 8J–8L), nine species such as *Lachnospiraceae_bacterium_609, Parabacteroides_goldsteini*, and others were changed simultaneously in both early and late intervention groups. (Figures 8D–8F and 8J–8L). In addition to HFD-fed mice, celastrol intervention also changed the composition of the gut microbiome of ND-fed mice at the genus (Figure S9A) and species levels (Figure S9B).

To further investigate the functional changes in the gut microbiome after celastrol treatment, we annotated genes to the Kyoto Encyclopedia of Genes and Genomes (KEGG) Orthology (KO) database (Kanehisa and Goto, 2000). Principal coordinate analysis (PCoA) of the relative abundance of all of the significantly altered KOs revealed significant shifts after celastrol treatment in DIO mice (Figure 8M) or early celastrol-treated HFD-fed lean mice (Figure 8N). The relative abundance of KEGG pathways predicted by phylogenetic reconstruction of unobserved states (PICRUSt) revealed that in both celastrol-treated DIO mice (Figures S10A and S10B) and HFD-fed lean mice treated early with celastrol (Figures S10B and S10P), changes in the gut microbiota were linked mainly to the enrichment of genes related to transporters, ATP-binding cassette (ABC) transporters, and transcription factors. These results indicated that the decrease of intestinal lipid transporters caused by celastrol might come from changes of the gut microbiota.

**Gut microbiota plays an important role in mediating the regulation of intestinal lipid transport by celastrol**

To determine whether the gut microbiota is necessary for the decrease in intestinal lipid transporters caused by celastrol, we treated HFD-induced obesity mice with antibiotics and celastrol. The data showed that mice in AH group had a rapid body weight gain (about 3 g) during first 3 days, then all the mice from the antibiotics-treated groups (AN, AH, and AHC groups) gained similar amount of body weight from day 3 to day 24 (Figure 9A). Compared with HFD mice with 34% body weight gain, antibiotics strikingly blocked body weight gain by around 50%, suggesting an important role of gut microbiota in high-fat diet-induced obesity (Figure 9A). During this period, we did not detect a significant change in the food intake of HFD-fed mice by celastrol, regardless of antibiotics intervention (Figure 9B). Consistent with the body weight change, the antibiotics enhanced the excretion of TG from the feces of HFD-fed mice (Figure 9C), which was not further affected by celastrol, indicating that celastrol-caused lipid excretion in feces could be depended on the modulation on gut microbiota. At the same time, the pathological differences in the intestine observed between celastrol-treated and untreated mice with normal intestinal commensal bacteria almost disappeared after antibiotics treatment (Figure 9D).

Finally, we observed a similar effect of antibiotics as celastrol on suppressing intestinal lipid transport-associated transporters and proteins such as CD36, ApoB, FATP4, and FABP2, which were not further affected by celastrol (Figures 9E and 9F).

Furthermore, we performed fecal microbiota transplantation (FMT) experiment to better clarify the role of gut microbiota in mediating the celastrol effect on lowering the body weight gain in HFD-induced obesity. The mice transplanted with fecal bacteria derived from HFD + CEL mice gained less body weight than the mice transplanted with fecal bacteria derived from HFD mice along with the reduced weight of fat tissues (Figures S11A and S11C–S11E), and there was no significant difference in the food intake between these two groups of mice with FMT (Figure S11B). Importantly, the mice transplanted with celastrol-conditioned
Figure 9. Modification of the gut microbiota by antibiotics blocks the celastrol-induced decrease in intestinal lipid absorption

(A–F) Eight-week-old C57BL/6J mice fed an ND or HFD supplemented with celastrol and/or antibiotics. (A) Body weight changes. (B) Food intake. (C) Fecal TG levels of mice during the treatments. (D) Representative H&E-stained images of the jejunum (200×). Scale bar, 50 μm. (E) Intestinal lipid-transport-related protein levels and (F) quantified signal intensity (n = 4–6 for each group). The dose of celastrol is 3 mg/kg/day. n = 10 in each group of ND, NC, HFD, and HC, and n = 6–7 in each group of AN, AH, and AHC. Error bars represent the mean ± SEM. p values were determined by two-way ANOVA (A) or one-way ANOVA. ***p < 0.001, **p < 0.01, *p < 0.05; n.s., not significant (p > 0.05). ND, normal diet; NC, normal diet supplemented with celastrol; HFD, high-fat diet; HC, high-fat diet plus celastrol; AN, antibiotics treatment plus normal diet; AH, antibiotics treatment plus high-fat diet; AHC, antibiotics treatment plus high-fat diet plus celastrol.
intestinal microbes showed higher levels of fecal TG and FFA compared with the mice transplanted with fecal bacteria derived from HFD mice (Figures S11F and S11G). These data indicated that the intestinal flora contributed to the weight loss effect of celastrol on HFD-fed mice.

**DISCUSSION**

Growing evidence indicates that celastrol could improve obesity and related comorbidities, suggesting that celastrol could be a new promising therapeutic strategy. As a natural pharmaceutical compound most likely to be developed into modern medicines, the mechanism of action of celastrol must be studied before it is finally deployed to the clinic (Corson and Crews, 2007). Several studies have been conducted on the mechanism of the weight loss effect of celastrol. Celastrol may exert its weight-loss effect by increasing the sensitivity of leptin signaling in the hypothalamus to reduce food intake (Feng et al., 2019; Kyriakou et al., 2018; Liu et al., 2015) or increasing energy expenditure by enhancing the function of brown fat (Ma et al., 2015). In addition, some studies have suggested that celastrol can reduce weight by mitigating oxidative stress (Wang et al., 2014) or inhibiting the differentiation of adipocytes (Hong et al., 2018). However, the subsequent research results did not fully support the previous conclusions (Pfuhlmann et al., 2018; Saito et al., 2019). Thus, the mechanism of the weight loss effect of celastrol is still controversial. In our study, we revealed that celastrol regulates intestinal flora to inhibit intestinal lipid absorption.

White adipose tissue (WAT) and brown adipose tissue (BAT) are the two principal types of adipose tissues in mammals. WAT stores energy in the form of TG (Gesta et al., 2007), whereas classical BAT is specialized at dissipating energy directly as heat through the high contents of mitochondrial UCP1 (Rosen and Spiegelman, 2014) and has attracted considerable research interest because of its therapeutic potential to treat obesity and obesity-associated metabolic diseases (Liu et al., 2013; Stanford et al., 2013). All our data from both cells and animals suggest that celastrol does not improve the function of brown fat directly and does not increase the energy expenditure of DIO mice by indirect calorimetry system. Recent reports suggested that the indirect calorimetry was not the gold standard to evaluate energy expenditure (Burnett and Grobe, 2014; Speakman, 2014). Especially, no difference in respirometry of our study might be affected by the altered gut microbiota, which was reported to result in decreased energy expenditure (Bahr et al., 2015). Thus, the effect of celastrol on energy consumption needs further in-depth study.

It is well known that in the process of evolution, the gut gained highly effective mechanisms for fat absorption. Intestinal lipid transport plays a central role in fat homeostasis. The fat content of the Western diet averages ~35% of energy intake and is mostly in the form of triglycerides (TGs). Dietary TG is hydrolyzed in the intestinal lumen by pancreatic lipases and generates two fatty acids (FAs) and one sn-2-monoacylglycerol (2-MG). These products are absorbed through the apical membrane of intestinal cells (Goldberg et al., 2009). In our study, we were surprised to observe that there was more food residue in the intestine of HFD-fed mice administered celastrol, and these mice could not form granular feces in the colon. In addition, the TG and FFA levels in the feces of mice treated with celastrol were higher. Celastrol has been reported to cause injuries to the anus, colon, and intestine (Zhao et al., 2019), but we did not observe this phenomenon in our experiment (data not shown). All these phenomena prompted us to put forth the idea that celastrol may inhibit lipid absorption in the intestinal tract of mice and thus protect against obesity caused by an HFD. The acute lipid absorption experiment confirmed our speculation based on the phenotype we observed.

Proteomic analysis of the intestine of DIO mice treated with celastrol revealed that celastrol significantly changed the abundance of a large number of proteins in the intestinal tissues. The KEGG pathway analysis of the proteome showed that the fat digestion and absorption pathways had changed significantly, with ApoB, FABP2, FATP2, and FATP4 being identified as important signaling molecules of that pathway. Small intestinal cells uptake long-chain FAs (LCFAs) via both passive diffusion and protein-facilitated FA transfer. ApoB is the requisite surface structural protein that facilitates the formation of lipoproteins within the ER (Cartwright and Higgins, 2001; Fisher and Ginsberg, 2002; Pariyarath et al., 2001). The current concept is that ApoB is an obligate requirement for intestinal lipoprotein biogenesis (Abumrad and Davidson, 2012). FABP2 is reported to contribute to the uptake of dietary fatty acids in intestine (Besnard et al., 2002; Levy et al., 2001). Fatty acid transport proteins (FATPs) are classified as members of the Solute Carrier 27 (Scl27) family of proteins based on their ability to function in the transport of exogenous fatty acids. Results from both knockdown and overexpression studies of several members of the FATP family
are consistent with the conclusion that they function in the process governing the transport of exogenous fatty acids into the cell in a highly regulated manner (Black et al., 2016). It has been confirmed that FATP2 expression in the small intestinal mucosa is significantly increased in mice fed an HFD and plays an important role in the transport of exogenous fatty acids (van den Bosch et al., 2007; Wisniewski et al., 2015). One member of this family, FATP4, located at the ER and subapical membranes, also mediates the apical uptake of long-chain fatty acids (Milger et al., 2006; Stahl et al., 1999). In addition to the proteins identified by the proteome, we also detected a significant decrease in the expression of CD36 in the intestinal tract of mice in the celastrol intervention group via WB. A large body of in vivo evidence from rodents and humans indicates that CD36 plays an important role in facilitating tissue FA uptake (Coburn et al., 2000; Hajri et al., 2002; Hirano et al., 2003; Watanabe et al., 1998). PPARα is a transcription factor and has been shown to be expressed at a high level in the small intestine (Bunger et al., 2007). In the small intestine, FATP2 expression levels are increased 4- to 5-fold in response to PPARα (Hirai et al., 2007). In our study, the decreased expression of PPARα by celastrol treatment may be an important cause of the downregulation of FATP2 expression. Overall, the significantly decreased expression of the proteins associated with intestinal lipid absorption in the intestine of celastrol-treated mice further demonstrated that intestinal lipid absorption was inhibited by celastrol.

Ob/ob mice have a large increase in food intake due to the lack of leptin, which in turn causes obesity even when fed an ND. It has been reported that the weight gain of ob/ob mice is not affected by celastrol (Liu et al., 2015). However, when we fed ob/ob mice an HFD supplemented with celastrol, the increase in BW was significantly inhibited with little change in food intake and a significant increase in fecal TG content. This phenomenon was consistent with the results of DIO C57BL/6 mice treated with celastrol, indicating that the effect of celastrol on BW is food-type dependent and that celastrol is more suitable for protecting against obesity caused by HFD. Previous findings from ob/ob mice showing the resistance to celastrol in treating obesity could be due to the diet difference.

Consistent with the reported phenomenon (Ma et al., 2015; Zhang et al., 2017), celastrol significantly improved the degree of fatty liver in DIO C57BL/6 mice in our study. It cannot be ruled out that the improvement in fatty liver was due to a decrease in food intake caused by administration of celastrol. However, what is amazing is that the same phenomenon occurred in ob/ob mice fed an HFD, yet the food intake of these mice was not reduced by celastrol treatment. This indicates that the decrease in lipid absorption in mice may be the main reason for the improvement in fatty liver in these celastrol-treated obese mice.

The intestinal flora promotes the absorption of fat from the diet and therefore plays an important role in the development of obesity (Gentile and Weir, 2018), and antibiotics can suppress HFD-induced body weight gain (Liu et al., 2019). Studies have shown that the intestinal flora can regulate the expression of intestinal lipid transporters (Kuang et al., 2019). In our research, we found that celastrol significantly changed the composition of intestinal microbes in HFD-fed mice and reversed some of the changes caused by HFD. The functional prediction of the changed flora showed that the change in the flora mainly affected the lipid transporters. Moreover, continuous antibiotic treatment depleting these changed gut bacteria abrogated the beneficial effects of celastrol supplementation on HFD-fed mice. Further analysis found that the intervention of antibiotics abolished the regulation of celastrol on intestinal transporters in HFD-fed mice. We noticed that the use of antibiotics weakened the capability of celastrol in inhibiting HFD-induced obesity and intestinal lipid transport, suggesting that the regulation on intestinal flora could be a critical mechanism of celastrol in attenuating HFD-induced obesity.

Our data were not consistent with previous findings in leptin signaling modulation and energy expenditure regulation (Fang et al., 2019; Kyriakou et al., 2018; Liu et al., 2015; Ma et al., 2015). Actually, recent publications also opposed each other on above mechanisms (Pfuhlmann et al., 2018; Saito et al., 2019). Our explanations could be as follows: (1) the secondary effect of body weight loss could affect leptin signaling and mitochondrial function in metabolic tissues. It is known that lean mice could have improved leptin signaling sensitivity and mitochondrial function in metabolic tissues. The long-term celastrol treatment led to a better metabolic condition due to the loss of fat mass, which may subsequently affect the leptin signaling sensitivity and mitochondrial metabolism. (2) The use of different animal models: as we know, the body weight gain of db/db or ob/ob mice is caused by the enhanced food intake but not
high-fat diet. Our data strongly suggested that celastrol inhibited intestinal lipid absorption to improve obesity. Thus, under the obese conditions not related to high-fat diet, an anti-obesity effect of celastrol should be disappeared. (3) Other unexpected factors such as animal genetic background and the length and time points of celastrol treatment during the setup of experiments might also affect the data and conclusion.

In conclusion, we demonstrated that celastrol attenuates HFD-induced obesity by inhibiting intestinal lipid absorption and intestinal flora resetting rather than by increasing leptin signaling sensitivity and brown fat function. Our studies reveal a mechanism contributing to the celastrol effect on treating obesity.

Limitations of the study
In this study, we clarified that celastrol inhibited the HFD-induced obesity by lowering the intestinal lipid digestion and absorption. Further evidence showed that the changes in the composition of intestinal microbes could mediate celastrol effect on the intestinal lipid transport. However, this study had a couple of limitations: (1) we did not define the specific bacteria mediating the celastrol effect on lowering the intestinal lipid transport and digestion. (2) We did not define the specific metabolites released from the bacteria and more detailed mechanisms that contributed to the regulatory effect of celastrol on intestinal lipid transport and digestion in obesity induced by high-fat diet.

Resource availability
Lead contact
Further information and requests for resources and reagents should be directed to and will be fulfilled by the Lead Contact, Zhanjun Jia (jiazj72@hotmail.com).

Materials availability
This study did not generate new unique reagents.

Data and code availability
Data supporting the findings of this study are available within the paper and its Supplemental information and also from the authors upon reasonable request.

METHODS
All methods can be found in the accompanying Transparent methods supplemental file.

SUPPLEMENTAL INFORMATION
Supplemental information can be found online at https://doi.org/10.1016/j.isci.2021.102077.

ACKNOWLEDGMENTS
This work was supported by grants from the National Natural Science Foundation of China (81873599 to Z.J., 82000642 to H.H., 81570616 to Y.Z., and 81830020to A.Z.).

AUTHOR CONTRIBUTIONS
H. H., Y. Z., F. Z., K. C., T. W., and Q. L. conducted the experiments. Z. J., H. H., Y. Z., A. Z., and S. H. designed the experiments and wrote the paper. Data were analyzed by H. H., Y. Z., and Z. J., A. Z., and S. H. supervised whole research work. All authors approved the final version of the manuscript.

DECLARATION OF INTERESTS
The authors declare no competing interests.

Received: June 22, 2020
Revised: July 22, 2020
Accepted: January 14, 2021
Published: February 19, 2021
REFERENCES

Abumrad, N.A., and Davidson, N.O. (2012). Role of the gut in lipid homeostasis. Physiol. Rev. 92, 1061–1085.

Adams, T.D., Davidson, L.E., Litwin, S.E., Kim, J., Kolotkin, R.L., Nanjee, M.N., Gutierrez, J.M., Froglley, S.J., Ibele, A.R., Brinton, E.A., et al. (2017). Weight and metabolic outcomes 12 Years after gastric Bypass. N. Engl. J. Med. 377, 1143–1155.

Allison, A.C., Cacabelos, R., Lombardi, V.R., Alvarez, X.A., and Vigo, C. (2001). Celastrol, a potent antioxidant and anti-inflammatory drug, as a possible treatment for Alzheimer’s disease. Prog. Neuropsychopharmacol. Biol. Psychiatry 25, 1341–1357.

Axlung, U., Olsson, C., Xu, J., Fernandez, C., Larsson, S., Strom, K., Ahrene, S., Holm, C., Molin, G., and Berger, K. (2012). Green tea powder and Lactobacillus plantarum affect gut microbiota, lipid metabolism and inflammation in high-fat fed C57BL/6J mice. Nutr. Metab. (Lond) 9, 105.

Bahr, S.M., Weidemann, B.J., Castro, A.N., Walsh, J.W., deLeon, O., Grobe, J.L., and Kirby, J.R. (2015). Raspendin-induced weight gain is mediated through shifts in the gut microbiome and suppression of energy expenditure. EBioMedicine 2, 1725–1734.

Besnard, P., Niot, I., Poirier, H., Clement, L., and Besnard, P., Niot, I., Poirier, H., Clement, L., and Kersten, S., Hooiveld, G.J., and Muller, M. (2016). Pathophysiology of human genetic CD36 knockouts. J. Biol. Chem. 281, 35253–35259.

Collaborators, G.B.D.O., Alshin, A., Forouzanfar, M.H., Reitsma, M.B., Sur, P., Estep, K., Lee, A., Marzack, L., Mokdad, A.H., Moradi-Lakeh, M., et al. (2017). Health effects of overweight and obesity in 195 countries over 25 years. N. Engl. J. Med. 377, 13–27.

Cordain, L., Eaton, S.B., Sebastian, A., Mann, N., Lindeberg, S., Watkins, B.A., O’Keefe, J.H., and Brand-Miller, J. (2002). Origins and evolution of the Western diet: health implications for the 21st century. Am. J. Clin. Nutr. 81, 341–354.

Corson, T.W., and Crews, C.M. (2007). Molecular understandings of traditional medicines: triumphs and trials. Cell 130, 769–774.

Fang, P., He, B., Yu, M., Shi, M., Zhu, Y., Zhang, Z., and Bo, P. (2019). Treatment with celastrol protects against obesity through suppression of galanin-induced fat intake and activation of PGC-1alpha/GLUT4 axis-mediated glucose consumption. Biochim. Biophys. Acta Mol. Basis Dis. 1865, 1341–1350.

Feng, X., Guan, D., Auen, T., Choi, J.W., Salazar Hernandez, M.A., Lee, J., Chun, H., Faruk, F., Kaplun, E., Herbert, Z., et al. (2019). IL1R1 is required for celastrol’s leptin-sensitization and anti-obesity effects. Nat. Med. 25, 575–582.

Fisher, E.A., and Ginsberg, H.N. (2002). Complexity in the secretory pathway: the assembly and secretion of apolipoprotein B-containing lipoproteins. J. Biol. Chem. 277, 17377–17380.

Gentile, C.L., and Weir, T.L. (2018). The gut microbiota at the intersection of diet and human health. Science 362, 776–780.

Gesta, S., Tseng, Y.H., and Kahn, C.R. (2007). Developmental origin of fat: tracking obesity to its source. Cell 131, 242–256.

Goldberg, I.J., Eckel, R.H., and Abumrad, N.A. (2009). Regulation of fatty acid uptake into tissues: lipoprotein-lipase- and CD36-mediated pathways. J. Lipid Res. 50 (Suppl.), S56–S90.

Guven, S., El-Bershawi, A., Sonnenberg, G.E., Wilson, C.R., Hoffmann, R.G., Krakower, G.P., and Kissebah, A.H. (1999). Plasma leptin and insulin levels in weight-reduced obese women with normal body mass index: relationships with body composition and insulin. Diabetes 48, 347–352.

Hajit, T., Han, X.X., Bonen, A., and Abumrad, N.A. (2000). Defective fatty acid uptake modulates insulin responsiveness and metabolic responses to diet in CD36-null mice. J. Clin. Invest. 109, 1381–1389.

Haslam, D.W., and James, W.P. (2005). Obes. Lancet 366, 1197–1209.

Hirai, T., Fukushima, Y., and Motojima, K. (2007). PPARalpha agonists positively and negatively regulate the expression of several nutrient/drug transporters in mouse small intestine. Biol. Pharm. Bull. 30, 2185–2190.

Hirano, K., Kuwasako, T., Nakagawa-Toyama, Y., Janabi, M., Yamashita, S., and Matsuzawa, Y. (2009). Pathophysiology of human genetic CD36 deficiency. Trends Cardiovasc. Med. 13, 136–141.

Hong, W., Park, J., Yun, W., Kang, P.J., Son, D., Jung, J., Kim, J.Y., and You, S. (2018). Inhibitory effect of celastrol on adipogenic differentiation of human adipose-derived stem cells. Biochem. Biophys. Res. Commun. 507, 236–241.

Hu, M., Luo, Q., Altingbieke, G., Chong, S., Xu, C., Xie, L., Chen, X., Zhang, D., Zhou, Y., Wang, Z., et al. (2017). Celastrol-induced Nur77 interaction with TRAF2 alleviates inflammation by promoting mitochondrial ubiquitination and autophagy. Mol. Cell 66, 141–153.e64.

Kanehisa, M., and Goto, S. (2000). KEGG: kyoto encyclopedia of genes and genomes. Nucl. Acids Res. 28, 27–30.

Kashyap, D., Sharma, A., Tuli, H.S., Sak, K., Mukherjee, T., and Bishayee, A. (2018). Molecular targets of celastrol in cancer: recent trends and advancements. Crit. Rev. Oncol. Hematol. 128, 70–81.

Kim, B.S., Song, M.Y., and Kim, H. (2014). The anti-obesity effect of Ephedra sinica through modulation of gut microbiota in obese Korean women. J. Ethnopharmacol 152, 532–539.

Kuang, Z., Wang, Y., Li, Y., Ce, Y., Ruhn, K.A., Behrendt, C.L., Olson, E.N., and Hooper, L.V. (2019). The intestinal microbiota programs diurnal rhythms in host metabolism through histone deactylase 3. Science 365, 1428–1434.

Kyrkou, E., Schmidt, M., Dodd, G.T., Puflahmann, K., Smirnina, S.E., Lenhart, D., Greulich, F.A., Schricker, S.C., De Angelis, M., Schramm, K.W., et al. (2018). Celastrol promotes weight loss in diet-induced obesity by inhibiting the protein tyrosine phosphatases PTP1B and TCPTP in the hypothalamus. J. Med. Chem. 61, 11144–11157.

Lee, J.H., Koo, T.H., Yoon, H., Jung, H.S., Jin, H.Z., Lee, K., Hong, Y.S., and Lee, J.J. (2006). Inhibition of NF-kappa B activation through targeting I kappa B kinase by celastrol, a quinone methide triterpenoid. Biochem. Pharmacol. 72, 1311–1321.

Levy, E., Menard, D., Delvin, E., Stan, S., Mitchell, G., Lambert, M., Ziv, E., Feoli-Fonseca, J.C., and Seidman, E. (2001). The polymorphism at codon 54 of the FABP2 gene increases fat absorption in

iScience Article

OPEN ACCESS

iScience 24, 102077, February 19, 2021
human intestinal explants. J. Biol. Chem. 276, 39679–39685.

Li, J., Song, J., Zaytseva, Y.Y., Liu, Y., Rychahou, P., Jiang, K., Starr, M.E., Kim, J.T., Harris, J.W., Yiannikouris, F.B., et al. (2016). An obligatory role for neurotensin in high-fat-diet-induced obesity. Nature 533, 411–415.

Liu, X., Zheng, Z., Zhu, X., Meng, M., Li, L., Shen, Y., Chi, Q., Wang, D., Zhang, Z., Li, C., et al. (2013). Brown adipose tissue transplantation improves whole-body energy metabolism. Cell Res 23, 851–854.

Liu, J., Lee, J., Salazar Hernandez, M.A., Mazitschek, R., and Ozcan, U. (2015). Treatment of obesity with celastrol. Cell 161, 999–1011.

Liu, D., Wen, B., Zhu, K., Luo, Y., Li, J., Li, Y., Lin, H., Huang, J., and Liu, Z. (2019). Antibiotics-induced perturbations in gut microbial diversity influence metabolic phenotypes in a murine model of high-fat-diet-induced obesity. Appl. Microbiol. Biotechnol. 103, 5269–5283.

Losacco, M.C., de Almeida, C.F.T., Hijo, A.H.T., Losacco, M.C., de Almeida, C.F.T., Hijo, A.H.T., Bargi-Souza, P., Gama, P., Nunes, M.T., and Losacco, M.C., de Almeida, C.F.T., Hijo, A.H.T., Bargi-Souza, P., Gama, P., Nunes, M.T., and Goulart-Silva, F. (2018). High-fat diet affects gut nutrients transporters in hypo and hyperthyroid mice by PPAR-α independent mechanism. Life Sci. 203, 321–328.

Lynes, M.D., and Widmaier, E.P. (2011). Involvement of CD36 and intestinal alkaline phosphatases in fatty acid transport in enterocytes, and the response to a high-fat diet. Life Sci. 88, 384–391.

Ma, X., Xu, L., Alborebello, A.T., Gavilova, O., Bagattin, A., Scarselli, M., Liu, J., Finkel, T., and Mueller, E. (2015). Celastrol protects against obesity and metabolic dysfunction through activation of a HSF1-PGC1α transcriptional axis. Cell Metab. 22, 695–708.

Martinez-Guyun, K., Hubert, N., Frazier, K., Urelis, S., Musch, M.W., Ojeda, P., Pierre, J.F., Miyoshi, J., Sontag, T.J., Cham, C.M., et al. (2018). Small intestine microbiota regulate host digestive and absorptive adaptive responses to dietary lipids. Cell Host Microbe 23, 458–469.e55.

Milger, K., Herrmann, T., Becker, C., Gotthardt, D., Zickwolf, J., Ehehelt, R., Watkins, P.A., Stremmel, W., and Fullekrug, J. (2006). Cellular uptake of fatty acids driven by the ER-localized acyl-CoA synthetase FATP4. J. Cell Sci 119, 4678–4688.

Olshansky, S.J., Passaro, D.J., Hershov, R.C., Layden, J., Carnes, B.A., Brody, J., Hayflick, L., Butler, R.N., Allison, D.B., and Ludwig, D.S. (2005). A potential decline in life expectancy in the United States in the 21st century. N. Engl. J. Med. 352, 1136–1145.

Padwal, R.S., and Majumdar, S.R. (2007). Drug treatments for obesity: orlistat, sibutramine, and rimonabant. Lancet 369, 71–77.

Pang, X., Yi, Z., Zhang, J., Lu, B., Sung, B., Qu, W., Aggarwal, B.B., and Liu, M. (2010). Celastrol suppresses angiogenesis-mediated tumor growth through inhibition of Akt/mammalian target of rapamycin pathway. Cancer Res. 70, 1951–1959.

Parnyarth, R., Wang, H., Atchison, J.D., Ginsberg, H.N., Welch, W.J., Johnson, A.E., and Fisher, E.A. (2001). PPARγ-mediated interactions of apoprotein B with the ribosome and translocon during lipoprotein assembly or targeting to the proteasome. J. Biol. Chem. 276, 541–550.

Pfuhlmann, K., Schriefer, S.C., Baumann, P., Kabra, D.G., Jiang, J., Singh, U., Berglund, E.D., Grobe, J.L., Pariyarath, R., Wang, H., Aitchison, J.D., Aggarwal, B.B., and Liu, J., Finkel, T., and Fisher, E.A. (2001). Co-translational interactions of apoprotein B with the ribosome and translocon during lipoprotein assembly or targeting to the proteasome. J. Biol. Chem. 276, 541–550.

Rosen, E.D., and Spiegelman, B.M. (2014). What we talk about when we talk about fat. Cell 154, 20–44.

Saito, K., Davis, K.C., Morgan, D.A., Toth, B.A., Saito, K., Davis, K.C., Morgan, D.A., Toth, B.A., Jiang, J., Singh, U., Berglund, E.D., Grobe, J.L., Rahman, K., and Cui, H. (2019). Celastrol reduces obesity in MC4R deficiency and stimulates sympathetic nerve activity affecting metabolic and cardiovascular functions. Diabetes 68, 1210–1220.

Semova, I., Carter, J.D., Stombaugh, J., Mackey, L.C., Knight, R., Farber, S.A., and Rawls, J.F. (2012). Microbiota regulate intestinal absorption and metabolism of fatty acids in the zebrafish. Cell Host Microbe 12, 277–288.

Shimizu, I., Aprahamian, T., Kikuchi, R., Shimizu, I., Aprahamian, T., Kikuchi, R., Shimizu, I., Aprahamian, T., Kikuchi, R., and Walsh, K. (2014). Vascular rarefaction mediates whitening of brown fat. J. Clin. Invest. 124, 2099–2112.

Speakman, J.R. (2014). Should we abandon indirect calorimetry as a tool to diagnose energy expenditure? Not yet. Perhaps not ever. Commentary on Burnett and Grobe (2014). Mol. Metab. 3, 342–344.

Stahl, A., Hirsch, D.J., Gimeno, R.E., Punreddy, S., Ge, P., Watson, N., Patel, S., Kotler, M., Raimondi, A., Tartaglia, L.A., et al. (1999). Identification of the major intestinal fatty acid transport protein. Mol. Cell 4, 299–308.

Stanford, K.I., Middelbeek, R.T., Townsend, K.L., An, D., Nygaard, E.B., Hitchcox, K.M., Markan, K.R., Nakano, K., Hirshman, M.F., Tseng, Y.H., et al. (2013). Brown adipose tissue regulates glucose homeostasis and insulin sensitivity. J. Clin. Invest. 123, 215–223.

de Vogel-van den Bosch, H.M., Bunger, M., de Groot, P.J., Bosch-Vermeulen, H., Hooiveld, G.J., and Muller, M. (2008). PPARalpha-mediated effects of dietary lipids on intestinal barrier gene expression. BMC Genomics 9, 231.

Wang, C., Shi, C., Yang, X., Yang, M., Sun, H., and Wang, C. (2014). Celastrol suppresses obesity process via increasing antioxidant capacity and improving lipid metabolism. Eur. J. Pharmacol. 744, 52–58.

Watanabe, K., Ohta, Y., Toba, K., Ogawa, Y., Hanawa, H., Hirokawa, Y., Kodama, M., Tanabe, N., Hirano, S., Ohkura, Y., et al. (1998). Myocardial CD36 expression and fatty acid accumulation in patients with type I and II CD36 deficiency. Ann. Nucl. Med. 12, 261–266.

Wei, C., Wang, X., Yao, X., Xi, F., He, Y., Xu, Y., Ma, L., Chen, X., Zhao, C., Du, R., et al. (2019). Bifenthrin induces fat deposition by improving fatty acid uptake and inhibiting lipolysis in mice. J. Agic. Food Chem. 67, 14046–14055.

Wisniewski, J.R., Friedrich, A., Keller, T., Mann, M., and Koepsell, H. (2015). The impact of high-fat diet on metabolism and immune defense in small intestine mucosa. J. Proteome Res. 14, 353–365.

Zhang, Y., Geng, C., Liu, X., Li, M., Gao, M., Liu, X., Fang, F., and Chang, Y. (2017). Celastrol ameliorates liver metabolic damage caused by a high-fat diet through Sirt1. Mol. Metab. 6, 138–147.

Zhao, J., Luo, D., Zhang, Z., Fan, N., Wang, Y., Nie, H., and Rong, J. (2019). Celastrol-loaded PEG-PCL nanomicelles ameliorate inflammation, lipid accumulation, insulin resistance and gastrointestinal injury in diet-induced obese mice. J. Control Release 310, 188–197.
Supplemental Information

Celastrol inhibits intestinal lipid absorption by reprofiling the gut microbiota to attenuate high-fat diet-induced obesity

Hu Hua, Yue Zhang, Fei Zhao, Ke Chen, Tong Wu, Qianqi Liu, Songming Huang, Aihua Zhang, and Zhanjun Jia
Figure S1. Celastrol does not increase the energy expenditure of DIO C57BL/6 mice, Related to Figure 1.

(A-H) The energy expenditure and home-cage activity of DIO C57BL/6 mice were examined for 3 days using the TSE system (n = 6 for each group). (A and B) Oxygen (O$_2$) consumption, (C and D) carbon dioxide (CO$_2$) production, (E and F) respiratory exchange rate, (G) heat production, (H) cumulative moving distance (DistK). The gray parts of figures A, C and E represent the dark phase, and the rest represent the light phase. Error bars represent the mean ± SEM. p values were determined by Student’s t test. **p < 0.001; n.s., not significant (p > 0.05).
Figure S2. Celastrol does not enhance the function of brown fat in vitro, Related to Figure 1.

(A) The viability of primary brown adipose precursor cells was analyzed by the CCK-8 assay after treatment with celastrol for 24 h at concentrations ranging from 50 nM to 800 nM (n = 6 for each group). (B and C) Gene expression analysis of mitochondrial and brown fat gene programs in differentiated primary brown fat cells treated with celastrol for (B) 48 h and (C) 96 h (n = 3 for each group). (D) Representative western blot of UCP1 in differentiated primary brown fat cells treated with celastrol for 48 h and 96 h. (E) Western blots of UCP1 in differentiated primary brown fat cells exposed to FFA (200 μM) and treated with celastrol for 24, 48, 72 and 96 h. Error bars represent the mean ± SEM. p values were determined by Student’s t test. *p < 0.05, **p < 0.01; n.s., not significant (p > 0.05).
Figure S3. Celastrol alleviates hepatic steatosis in DIO C57BL/6 mice or ob/ob mice fed a HFD, Related to Figure 1 and 4.

(A-C) DIO C57BL/6 mice were subjected to oral administration of celastrol (3 mg/kg/day) for 3 weeks. (A) The representative gross appearance, representative H&E-stained images (200×) and representative Oil red O-stained images (200×) of liver from DIO C57BL/6 mice treated with celastrol or not. Scale bar, 50 μm. (B) The liver weight and (C) liver TG levels of DIO C57BL/6 mice treated with celastrol or not (n = 8 for each group). (D-F) HFD-fed obese ob/ob mice were subjected to oral administration of celastrol for 6 weeks. (D) The representative gross appearance, representative H&E-stained images (200×) and representative Oil red O-stained images (200×) of liver from HFD-fed obese ob/ob mice treated with celastrol or not. Scale bar, 50 μm. (E) The liver weight and (F) liver TG levels of HFD-fed obese ob/ob mice treated with celastrol or not (n = 6 for each group). Error bars represent the mean ± SEM. p values were determined by Student’s t test. *p < 0.05, **p < 0.01, ***p < 0.001.
Figure S4. Celastrol treatment by intraperitoneal injection inhibits body weight gain and intestinal lipid transporter expression in mice fed a HFD, Related to Figure 1 and Figure 2.

(A-J) HFD-fed C57BL/6 mice were daily treated with vehicle or celastrol (100 μg/kg) intraperitoneally (i.p.) for 8 weeks. (A) The BW of each group of mice during the treatment. (B) The average 3-day food intake of each group of mice during the first week of treatment. (C-D) Weights of (C) eWAT and (D) liver of each group of mice. (E) Representative pictures of isolated intestines of mice in each group. (F-G) The relative fecal (F) TG and (G) FFA levels in each group of mice. (H-J) mRNA levels of intestinal lipid transport-related genes of mice treated with celastrol or not. n=6 for each group. Error bars represent the mean ± SEM. p values were determined by two-way ANOVA (A) or Student’s t test. *p < 0.05, **p < 0.01, ***p < 0.001; n.s., not significant (p > 0.05).
Figure S5. Effect of celastrol treatment on the expression of enteroendocrine related genes in HFD mice, Related to Figure 3.

(A-C) mRNA levels of intestinal enteroendocrine related genes in HFD mice treated with or without celastrol (n = 8 for each group). (D-E) The relative intestinal protein levels of Sct and Gip analyzed by proteomics (n = 3 for each group). Error bars represent the mean ± SEM. p values were determined by Student’s t test. *p < 0.05, **p < 0.01; n.s., not significant (p > 0.05).
Figure S6. Safety evaluation of celastrol treatment in HFD-fed ob/ob mice, Related to Figure 4.

(A-G) Serum levels of (A) alanine aminotransferase (ALT), (B) aspartate aminotransferase (AST), (C) lactate dehydrogenase (LDH), (D) blood urea nitrogen (BUN), (E) serum creatinine (SCr), (F) total cholesterol (TC) and (G) triglyceride (TG) in HFD-fed ob/ob mice treated with celastrol or not (n = 6 for each group). Error bars represent the mean ± SEM. p values were determined by Student's t test. *p < 0.05, **p < 0.01; n.s., not significant (p > 0.05).
Figure S7. Early celastrol intervention did not upregulate the expression of the mitochondrial and brown fat genes, Related to Figure 6.
ND- or HFD-fed C57BL/6 mice were subjected to oral administration of celastrol (3 mg/kg/day) for 24 days. Gene expression analysis of mitochondrial and brown fat gene programs in BAT of each group of mice by qRT-PCR (n = 10 for each group). Error bars represent the mean ± SEM. p values were determined by Student’s t test. **p < 0.01; n.s., not significant (p > 0.05).

Figure S8. Rarefaction curves for feces samples, Related to Figure 8.
(A-B) Rarefaction curves for samples from (A) DIO mice treated with celastrol (n = 7 for each group) or (B) early celastrol-treated HFD-fed mice (n = 10 for each group). ND, normal diet; NDC, normal diet plus celastrol; HFD, high-fat diet; HFDC, high-fat diet plus celastrol.
Figure S9. Gut microbiota with significant differences in relative abundance in ND-fed mice treated or not treated with celastrol, Related to Figure 8.

(A-B) Significantly different intestinal microbiota (A) at the genus level or (B) at the species level between ND-fed mice and ND-fed C57BL/6 mice treated with celastrol (3 mg/kg/day). ND, normal diet; NC, normal diet supplemented with celastrol. n = 10 for each group. p values were determined by the t test. 0.01< *p < 0.05, 0.001< **p < 0.01, 0.0001< ***p<0.001, ****p<0.0001.
Figure S10. Celastrol treatment promotes functional shifts in the gut microbiota, Related to Figure 8.

(A-B) DIO mice (n=7 for each group) or HFD-fed lean C57BL/6 mice (n=10 for each group) were subjected to oral administration of celastrol (3 mg/kg/day). Mouse fecal samples were taken and subjected to 16S RNA gene sequencing. (A-B) Pathway-enrichment analysis profiling of samples taken from (A) DIO mice treated with celastrol or (B) early celastrol-treated HFD-fed lean mice. ND, normal diet; HFD, high-fat diet; HFDC, high-fat diet supplemented with celastrol.
Figure S11. Transplantation of fecal microbiota from celastrol-treated obese mice reduces the body weight gain of HFD mice, Related to Figure 9.

(A-G) HFD-fed C57BL/6 mice were transplanted with fecal bacteria derived from HFD or HFD+CEL mice. (A) The BW of each group of mice during the treatment. (B) The average 3-day food intake of each group of mice during the treatment. (C-E) Weights of (C) eWAT, (D) iWAT and (E) pWAT of each group of mice. (F-G) The fecal (F) TG and (G) FFA levels in each group of mice. n=5 for HFD+PBS-FMT group and n=7 for HFD+HFD-FMT or HFD+HFDC-FMT group. Error bars represent the mean ± SEM. p values were determined by two-way ANOVA (A) or one-way ANOVA (B-G). *p < 0.05, **p < 0.01, ***p < 0.001; n.s., not significant (p > 0.05).

HFD+PBS-FMT, PBS gavage plus high-fat diet; HFD+HFD-FMT, transplanted with fecal bacteria derived from HFD mice plus high-fat diet; HFD+HFDC-FMT, transplanted with fecal bacteria derived from HFD+CEL mice plus high-fat diet.
TRANSPARENT METHODS

Animal experiments

(i) Determination of the effects of celastrol on mouse weight gain

Male C57BL/6J mice (8-week old) and ob/ob mice (4-week old) were purchased from the Model Animal Research Center of Nanjing University (Nanjing, China). The mice were maintained under a 12-h/12-h light/dark cycle at 22 ± 2°C and a relative humidity of 55 ± 10%. For treatments of lean C57BL/6J mice, celastrol was mixed with powdered chow (Beijing Keao Xieli Feed Co., Ltd., China) or HFD chow (60%, ResearchDiets, D12492) at a dose of 3 mg/kg/d. For treatments of ob/ob mice, celastrol at the same concentration used in DIO C57BL/6J mice (equivalent to 55.2 ppm) was mixed with HFD chow (60%, ResearchDiets, D12492). The food intake of all mice was measured once a day for 3 consecutive days. Parameters such as fat weight and liver weight were measured at the end of the treatment.

(ii) Determination of the causal role of microbiota in the anti-obesity effects of celastrol

(a) Analysis of gut microbiota. (1) DNA extraction. Fecal samples of mice were collected directly into sterile tubes and stored at -80°C until DNA extraction. DNA was extracted using a QIAamp DNA Stool Mini Kit (QIAGEN, Hilden, Germany) and then purified as a template for polymerase chain reaction (PCR) amplification. (2) PCR amplification of 16S rRNA genes and MiSeq sequencing. PCR amplification of the V4-V5 region of the 16S rRNA gene was performed using general bacterial primers (515F 5'-GTGCCAGCMGCCGCGGTAA-3' and 926R 5'-CCGTCAATTCMTTTGAGTTT-3'). The recovered product was used as a template for an 8-cycle PCR amplification to add the adapters, sequencing primers, and barcode tag sequences required for sequencing on the Illumina platform to the ends of the target fragment. All PCR products were recovered using an AxyPrep DNA gel recovery kit (Axygen, China), and fluorescence quantification was performed using an FTC-3000TM Real-Time PCR instrument. After homogenization and mixing, the libraries were sequenced by 2×300 bp paired-end sequencing on the MiSeq platform using the MiSeq v3 Reagent Kit (Illumina). (3) Bioinformatic analysis. Sample reads were allocated to the original data based on the barcode to obtain the effective sequence of each sample. Paired-end (PE) reads for all samples were run through Trimmomatic (version 0.35) to remove low-quality base pairs. According to the overlap relationship between PE reads, the paired reads are stitched into a sequence using the FLASH program (version 1.2.11), and the quality of the sequence is filtered using mothur software (version 1.33.3) to obtain optimized sequences. The demultiplexed reads were clustered at 97% sequence identity into operational taxonomic units (OTUs) using UPARSE software. The OTU representative sequences were assigned for taxonomy against the Silva 128 database with a confidence score ≥ 0.6 by the classify.seqs command in mothur. OTU taxonomies (from phylum to species) were determined based on NCBI. Based on the above analysis, a series of statistical and visual analyses of community structure was performed. The alpha-diversity analyses were calculated using mothur and plotted by R, and the beta-diversity metrics were calculated using mothur and visualized with principal coordinate analysis (PCoA).

(b) Antibiotic-induced gut microbiota depletion. A subset of 8-week-old male C57BL/6J mice were randomly distributed into the following groups: group fed with the ND and treated with antibiotics in drinking water (AN, n=6), group fed with the HFD and treated with antibiotics in
drinking water (AH, n=7) and a group fed with HFD and treated with celastrol (3 mg/kg/d) and a combination of antibiotics in drinking water (AHC, n=7). The ND group (n=10), ND + celastrol (NC) group (n=10), HFD group (n=10), HFD + celastrol (HC) group (n=10) were also set up as the control groups. The broad-spectrum antibiotic cocktail (Sigma, USA) included ampicillin (500 mg/L), vancomycin (250 mg/L), neomycin sulfate (500 mg/L) and metronidazole (500 mg/L). Body weight was recorded every 3 days, and food intake was recorded once a day for 3 consecutive days.

(c) Fecal microbiota transplantation (FMT). To prepare the recipient mice, a separate cohort of male C57BL/6 mice (8 weeks old) received a cocktail of antibiotics in their drinking water for three consecutive days (ampicillin, 200 mg/kg; neomycin sulfate, 200 mg/kg; metronidazole, 200 mg/kg; and vancomycin, 100 mg/kg). After completion of the antibiotic treatment, mice were fasted overnight and randomly assigned to two groups: one group of mice received FMT from donor HFD-fed mice, the other group received FMT from donor HFD-fed C57BL/6 mice treated with celastrol. Fresh fecal matter was collected from HFD-fed C57BL/6 mice treated with or without celastrol (3 mg/kg/day) for FMT. Each FMT dose was prepared on the same day of FMT. Feces were sliced with a scalpel, homogenized in phosphate-buffered saline (PBS), vortexed twice, and incubated for 15 minutes at 37°C. Then the samples were vortexed again and spun at 800 rpm for 3 minutes. The aqueous fecal extract was given to recipients by gavage (200 μl each). FMT of mice were repeated on consecutive days (without fasting) for a total of seven FMT per mouse. All recipient mice had free access to HFD chow. The HFD mice treated with the same volume of PBS by gavage were used as control. The body weight and food intake were recorded after FMT treatment.

All animal experiments were performed according to the protocols approved by the Institutional Animal Care and Use Committee of Nanjing Medical University (IACUC14030112-1).

In vivo metabolic phenotype analysis
To assess metabolic parameters, 8-week-old male C57BL/6J mice were fed HFD chow with or without celastrol for 2 weeks. Energy expenditure and home-cage activity were assessed using a combined indirect calorimetry system (TSE System, Bad Homburg, Germany). Mice were housed individually and given free access to food and water. O2 consumption, CO2 production and heat generation were measured every 40 min for a total of 120 h (including 48 h of adaptation) to determine the respiratory quotient and energy expenditure. Home-cage locomotor activity was determined using a multidimensional infrared light beam system with beams scanning the bottom and top levels of the cage, and activity was expressed as beam breaks.

Western blotting (WB)
We lysed cells or homogenized tissues in protein lysis buffer (50 mmol/L Tris, 150 mmol/L NaCl, 10 mmol/L EDTA, 1% Triton X-100, 200 mmol/L sodium fluoride, supplemented with 1× protease inhibitor cocktail (Roche, 04693132001)). Then, the samples were centrifuged at 4°C and 14,000 rpm for 15 min, and the supernatant was collected. The protein concentration was determined using a BCA protein assay kit (Beyotime, China), and the samples were diluted in SDS sample buffer. Total protein was separated by SDS-PAGE and transferred onto PVDF membranes. The membranes were blocked by TBS-T (0.1% Tween 20 in TBS) containing 5%
nonfat milk for 1 h at room temperature and then incubated with primary antibodies against CD36 (1/1000; Abcam, UK), ApoB (1/500; Proteintech, China), FATP2 (1/500; Proteintech, China), FATP4 (1/500; Proteintech, China), GLUT2 (1/500; Proteintech, China), GLUT5 (1/500; Proteintech, China), PPARα (1/500; Proteintech, China), and UCP1 (1/1000; Abcam, UK), followed by the addition of HRP-labeled secondary antibodies (1/2500). β-Actin (1/5000; Bioworld, USA) was used as an internal control. The blots were visualized using the Bio-Rad ECL detection system. Densitometric analysis was performed using Image Lab software (Bio-Rad, USA).

**Quantitative real-time PCR (qRT-PCR)**

Total cell or tissue RNA was extracted with RNAiso Plus reagent (TaKaRa Biotechnology Co., Ltd., Dalian, China) following the manufacturer’s protocol. cDNA was synthesized with 1 μg of total RNA using PrimeScript™ Reverse Transcriptase (TaKaRa Biotechnology Co., Ltd., Dalian, China). qRT-PCR was conducted by SYBR Green Master Mix (Vazyme, Nanjing, China) on a QuantStudio 3 real-time PCR System (Applied Biosystems, Foster City, CA, USA). The primers used for PCR amplification are listed in Table S1. The cycling conditions were 95°C for 10 min, followed by 40 repeats of 95°C for 15 s and 60°C for 1 min. The mRNA levels were normalized to a GAPDH or 18S rRNA control and calculated using the comparative cycle threshold (ΔΔCt) method.

**Histological examination**

Tissues were fixed in 4% paraformaldehyde (PFA) for 24 h at room temperature and then dehydrated by a graded series of ethanol and paraffin embedded. Subsequently, the tissues were cut into 4-μm sections and stained with hematoxylin-eosin (H&E). The images were captured with an Olympus BX51 microscope (Olympus, Center Valley, PA). Adipose tissues were treated with 90% ethanol for 24 h before being fixed with 4% PFA, and the remaining steps were the same as above.

**Oil red O staining**

Oil red O (ORO) staining was used to observe lipid droplets in liver tissues. First, frozen liver sections (10 μm) were prepared using a Leica CM1900 cryostat (Leica, Germany). Then, the sections were placed in 60% isopropanol for 1 min and stained with the prepared Oil red O dye (Sigma) solution for 20 min. Then, 60% isopropanol was used to wash away the nonspecifically stained Oil red O dye solution, and the tissue sections were photographed using Olympus BX51 microscopy (Olympus, Center Valley, PA) in bright field.

**Isolation and differentiation of primary brown fat precursor cells**

Brown adipose tissues (BAT) were dissected from 4-week-old C57BL/6J mice, rinsed in phosphate-buffered saline (PBS), minced, and digested for 1 h at 37°C in 0.2% (w/v) type I collagenase (Sigma) in DMEM/F12 (Gibco) supplemented with 2% fatty-acid-free BSA. Adipocytes were filtered through a 200-mesh screen followed by three washes (centrifuged at 2000 rpm for 10 min) with PBS. The sediment was resuspended in DMEM/F12 with 10% fetal bovine serum (FBS) (Gibco). Two days after reaching confluence (day 0), the cells were induced to differentiate into adipocytes in induction medium I (DMEM/F12 containing 10%
FBS, 17 nM insulin (Sigma), 2 μg/ml dexamethasone (Sigma), 0.5 mM isobutylmethylxanthine (Sigma), 0.5 μM rosiglitazone (Sigma), 125 μM indomethacin (Sigma) and 1 nM triiodothyronine (T3) (Sigma)). After 2 days, induction medium I was replaced with induction medium II (DMEM/F12 supplemented with 10% FBS, 1 nM T3, 17 nM insulin, and 0.5 μM rosiglitazone) and replaced with fresh induction medium II every two days. Five days later, the precursor cells were differentiated into mature brown fat cells.

**Cell viability**

Cell viability was determined by the CCK-8 assay kit (KGA317, KeyGen Biotech, China). Briefly, the primary brown fat precursor cells were treated with celastrol (50 nM to 800 nM) for 24 h, and then 10 μl of CCK-8 reagent was added to the medium and incubated for 2 h. Finally, the absorbance was detected at 450 nm.

**Glucose tolerance tests (GTT)**

For the GTT, mice were fasted for 15 h (from 6 p.m. to 9 a.m.), and fasting blood glucose was detected (0 min). Then, 1.5 g glucose/kg BW was injected i.p., and tail blood glucose was measured using a handheld glucometer (Ascensia Breeze, Bayer Company, Leverkusen, Germany) at 15, 30, 60, 90, 120 and 150 min after glucose injection. The area under the curve (AUC) was determined by GraphPad Prism software (version 7.0, GraphPad Software, La Jolla, CA, USA).

**Lipid absorption studies**

Lean or DIO C57BL/6 mice were treated with celastrol at a dose of 3 mg/kg/d for 6 days. After fasting for 6 h, blood was collected from the lower jaw of the mice to detect the basal levels of TG. Then, the mice were fed olive oil (17 μl/g BW) by gavage, and blood was collected from the lower jaw 2 h later (2 h). The serum was separated by centrifugation (4°C, 2000 rpm), and the TG content was determined using a liquid sample TG assay kit (E1003, Applygen, Beijing, China) according to the manufacturer’s instructions.

**TG and free fatty acid (FFA) contents determination**

For TG and FFA levels in feces, 200 mg of dried feces was homogenized in 1 ml of the extract reagent provided by the kits. The concentrations of TG and FFA were examined using assay kits (TG assay kit: E1013, Applygen, Beijing, China; FFA assay kit: BC0595, Solarbio, Beijing, China) according to the manufacturers’ instructions. All measurements were adjusted to the starting fecal mass. For TG levels in liver tissues, 50 mg of the liver tissue was accurately weighed, and 1 ml of the lysate supplied by the kit was added for homogenization. The homogenized liver tissue was heated and centrifuged in the same manner as the extraction of fecal TG. Ten microliters of supernatant was used to detect TG levels according to the instructions of the kit.

**Serum biochemistry**

Mouse blood was collected from the inferior vena cava after anesthesia, and serum samples were collected by centrifugation at 2000 rpm for 10 min. The levels of serum alanine aminotransferase (ALT), aspartate aminotransferase (AST), lactate dehydrogenase (LDH),
serum creatinine (SCr), blood urea nitrogen (BUN), triglyceride (TG) and serum total cholesterol (TC) were evaluated using a serum biochemical autoanalyzer (Hitachi 7600 modular chemistry analyzer, Hitachi Ltd., USA).

**Enzyme-linked immunosorbent assay (ELISA)**
The circulating leptin levels were determined by ELISA kits (E-EL-M0039c, Elabscience, Wuhan, China) according to the manufacturer’s instructions.

**Proteomics analysis**
Three samples (n=3 in DIO or DIO plus Celastrol group) were obtained from DIO mice treated with celastrol or not. For each sample, 20 μg of protein was separated on a 12.5% SDS-PAGE gel, and protein bands were visualized by Coomassie Blue R-250 staining for quality control. The samples were then digested using trypsin, and after protein digestion, peptides were first quantified spectrophotometrically at OD280, and 100 μg of each peptide sample was labeled using a TMT Mass Tagging kit (Thermo Fisher Scientific, Rockford, IL) according to the manufacturer’s instructions. Peptides of the two groups were labeled with different TMT labels, equivalently mixed and fractionated using a High pH Reversed-Phase Peptide Fractionation kit (Thermo Fisher Scientific, Rockford, IL) according to the manufacturer’s instructions. Each fraction was loaded onto a reversed-phase trap column connected to the C18-reversed-phase analytical column in buffer A (0.1% formic acid) and separated with a linear gradient of buffer B (84% acetonitrile and 0.1% formic acid) at a flow rate of 300 nl/min for nano LC-MS/MS analysis. Liquid chromatography-mass spectrometry/MS (LC-MS/MS) analysis was performed on a Q Exactive mass spectrometer (Thermo Scientific) that was coupled to Easy nLC. Tandem mass spectrometry (MS/MS) spectra were searched using the MASCOT engine embedded in Proteome Discoverer. The differentially expressed proteins were identified by fold change values greater than ±1.2 and p < 0.05. KEGG pathway enrichment analyses were applied based on Fisher’s exact test.

**Untargeted metabolomics analysis**
Eighty milligrams of tissue was weighed, homogenized in 200 μl of water, and vortexed for 60 s. Then, 800 μl of methanol acetonitrile solution was added, followed by vortexing for 60 s, sonicating twice at low temperature for 30 min each time, and incubating at -20°C for 1 h to precipitate protein. After centrifuging the samples at 14,000 rcf at 4°C for 20 min, the supernatant was lyophilized and stored at -80°C. The samples were separated using an Agilent 1290 Infinity LC Ultra-High Performance Liquid Chromatograph (UHPLC) HILIC column and analyzed by mass spectrometry using a Triple TOF 5600 mass spectrometer (AB SCIEX). Then, exact mass matching (<25 ppm) and secondary spectrum matching were used to search in the laboratory’s self-built database to identify the structure of metabolites. After the data were preprocessed by Pareto-scaling, multidimensional statistical analysis and one-dimensional statistical analysis, including Student’s t-test and fold change analysis, were performed. The differential metabolites were identified by FC > 1.5 and p < 0.05. The volcanic map was drawn using R software.

**Statistical analysis**
All values are presented as the mean value ± SEM. GraphPad Prism (version 7.0, GraphPad Software, La Jolla, CA, USA) software was used for statistical analyses. Statistical significance was calculated by Student’s t test or by one-factor or two-factor ANOVA. Significance was accepted at *P* < 0.05.

### Table S1. Primers used for qRT-PCR, Related to Figure 1, 3, 5, S2, S4, S5 and S7

| Name   | Forward Primer (5’-3’)                     | Reverse Primer (5’-3’)                      |
|--------|--------------------------------------------|--------------------------------------------|
| CD36   | ATGGGCTGTGATCGGAAGACTG                     | GTCTTCCAAATAAGCATGTCTCC                   |
| ApoB   | AAGCACAATCCGAAAAGTACGT                    | CTCCAGCTCTACCTTTACAGTTGA                  |
| FATP2  | TCCTCCAAGATGTGCGGTACT                     | TAGGTGAGCGCTCTCGTCTCG                    |
| FATP4  | GCCACTGTCTCTGACACCTCA                     | AACCCCTGCTGGGTGACTG                      |
| SGLT1  | ATGCAGGCTGACATCTCGA                       | ACCAAGGGCTTTACATTTCA                     |
| GLUT2  | TCGAGAAGACAAGATCAGGAGGA                    | GCTGGTGACTGTAAGTGG                      |
| GLUT5  | CCAATATGGGTACCAAGCTG                      | GCGTCAAAGTGAAAGACTCAATTA                 |
| PPARY  | TCAGGGTACCAGCTACCGAG                       | CCGAATAGTTCGCGAAGA                      |
| Cytc   | AAATCTCCACCGTGCTTGCG                     | GGATTCCTCCTCCCGAGG                      |
| Cox4β  | TCGCCCCAGATCGCTGTGAAAGA                   | CAGTCAACGTTGAGGTCATC                    |
| Mcad   | ATGACGGAGAAGCAAGCAATTAGA                  | TCGTCACCATCTCTCTCTCTGCTT                 |
| UCP1   | TACCAAGCTGTGCGATGTCCA                     | GCACAAACATGATGACAGGTTCC                 |
| PPRM16 | CAGCAGGTGAAGCAGGATCCA                     | GCACAAACGAGAGTTGGATGACTG                |
| Cidea  | TGACATCCATGGGATTGCAAGAGC                   | CAGGTGGATGATGACAGG                      |
| Elov3  | TTCTCACCGCGGTGTTAAAAATGG                  | TCTCGAAGTCAAGGTTGATC                    |
| PGC-1α | CCCTGCCATATTGTTAAGACC                    | TGCTGCTGGTCTGTTTTC                     |
| Cck    | AGCAGGACACATCCAGACAG                     | ACAGATGGGTATTCGTAGTCTC                  |
| Sct    | AGACACTGACGGGAAGTATGACGTG                 | CTGGCTCCTCTAAGGGGCTGGA                  |
| Grip   | TGAGTTCGATCCATCATGCTAA                    | CAGTGACAGAAGTCTTGTTC                    |
| 18s rRNA| ACGGACAGATGACGAGA                       | GCCTCCACCAAATAGA                       |
| GAPDH  | GTCTTCACTACCATGGAGAAGG                    | TCAAGTGGATGACCTTGCCAG                   |